Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Change in Receivables (2024 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Change in Receivables for 3 consecutive years, with -$6.1 million as the latest value for Q1 2026.

  • For Q1 2026, Change in Receivables fell 175.58% year-over-year to -$6.1 million; the TTM value through Mar 2026 reached $16.1 million, up 67.24%, while the annual FY2025 figure was $30.4 million, 299.82% up from the prior year.
  • Change in Receivables hit -$6.1 million in Q1 2026 for Syndax Pharmaceuticals, down from $12.6 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $12.6 million in Q4 2025 and bottomed at -$6.1 million in Q1 2026.
  • Average Change in Receivables over 3 years is $3.5 million, with a median of $4.1 million recorded in 2024.
  • Year-over-year, Change in Receivables surged 207.52% in 2025 and then tumbled 175.58% in 2026.
  • Syndax Pharmaceuticals' Change in Receivables stood at $4.1 million in 2024, then soared by 207.52% to $12.6 million in 2025, then crashed by 148.73% to -$6.1 million in 2026.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$6.1 million, $12.6 million, and $5.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.